Background: Sleep-disordered breathing (SDB) is a treatable but markedly under-diagnosed condition of frequent breathing pauses during sleep. SDB is linked to incident cardiovascular disease, stroke, and other morbidity. However, the risk of mortality with untreated SDB, determined by polysomnography screening, in the general population has not been established.

Methods: An 18-year mortality follow-up was conducted on the population-based Wisconsin Sleep Cohort sample (n = 1522), assessed at baseline for SDB with polysomnography, the clinical diagnostic standard. SDB was described by the number of apnea and hypopnea episodes/hour of sleep; cutpoints at 5, 15 and 30 identified mild, moderate, and severe SDB, respectively. Cox proportional hazards regression was used to estimate all-cause and cardiovascular mortality risks, adjusted for potential confounding factors, associated with SDB severity levels.

Results: All-cause mortality risk, adjusted for age, sex, BMI, and other factors was significantly increased with SDB severity. The adjusted hazard ratio (HR, 95% CI) for all-cause mortality with severe versus no SDB was 3.0 (1.4,6.3). After excluding persons who had used CPAP treatment (n = 126), the adjusted HR (95% CI) for all-cause mortality with severe versus no SDB was 3.8 (1.6,9.0); the adjusted HR (95% CI) for cardiovascular mortality was 5.2 (1.4,19.2). Results were unchanged after accounting for daytime sleepiness.

Conclusions: Our findings of a significant, high mortality risk with untreated SDB, independent of age, sex, and BMI underscore the need for heightened clinical recognition and treatment of SDB, indicated by frequent episodes of apnea and hypopnea, irrespective of symptoms of sleepiness.

Keywords: Sleep-disordered breathing, sleep apnea, all-cause mortality, cardiovascular mortality, cohort

Citation: Young T; Finn L; Peppard PE; Szklo-Coxe M; Austin D; Nieto FJ; Stubbs R; Hla KM. Sleep disordered breathing and mortality: eighteen-year follow-up of the wisconsin sleep cohort. SLEEP 2008;31(8):1071-1078.

UNDERSTANDING THE HEALTH BURDEN OF SLEEP DISORDERED BREATHING (SDB), A HIGHLY PREVALENT CONDITION OF FREQUENT, INTERMITTENT breathing pauses during sleep, is critical.\(^1\)\(^-\)\(^4\) The prevalence of moderate or severe SDB is estimated to be at least 6% for US adults; moreover, 17% of adults are estimated to have mild or worse SDB.\(^5\) Prevalence will undoubtedly rise, because obesity, a causal factor for SDB, is increasing dramatically in adults and children.\(^6\) Despite the availability of effective treatment for SDB, and evidence that SDB contributes to significant morbidity, at least 75% of cases of severe SDB remain undiagnosed.\(^4\)\(^,\)\(^6\)

Cost-effective screening and treatment recommendations to decrease the burden of SDB depend on the overall magnitude of adverse outcomes, including mortality, attributable to untreated SDB. Although numerous prospective\(^7\)\(^-\)\(^10\) and cross-sectional studies\(^11\)\(^-\)\(^15\) have linked SDB to hypertension, cardiovascular disease, depression, motor vehicle crashes, cognitive impairment, and diminished quality of life, definitive evidence on the role of SDB in increased mortality, a major component of the total burden of disease, is lacking.

Disclosure Statement
This was not an industry supported study. The authors have indicated no financial conflicts of interest.

Submitted for publication June, 2008
Accepted for publication July, 2008
Address correspondence to: Terry Young, PhD, 1300 University Avenue: 1070 MSC, Madison WI 53705; Tel: (608) 263-5832; Fax: (608) 263-8828; E-mail: tbyoung@wisc.edu

SLEEP, Vol. 31, No. 8, 2008
laboratory polysomnography at baseline. In addition, we investigated the risk of cardiovascular and cerebrovascular mortality with SDB and explored use of continuous positive air pressure therapy (CPAP), the most common treatment for SDB, as a modifier of mortality risk.

METHODS

Sample

The Wisconsin Sleep Cohort Study, established in 1988, is a prospective population-based study of the natural history of SDB. The study has been reviewed and approved by the University of Wisconsin Institutional Review Board. The sample is based on a two-stage weighted sampling procedure, previously described.27 In brief, a random sample of men and women, ages 30-60, was recruited from a sampling frame of payroll records of several Wisconsin state agencies, with a complete range of job titles from unskilled to professional, for a survey of sleep characteristics and other factors.

Of 2940 survey participants invited to participate in the overnight polysomnography protocol, 1546 agreed (53%). Potential participation bias was evaluated with data on the entire sampling frame and survey respondents.5,27,28 Participants, compared with nonparticipants, had a slightly healthier profile, including less hypertension. Consistent with a healthy volunteer bias, mortality follow-up (to March 2008) of the entire sample showed a lower death rate among the cohort participants, compared to non-participants. After exclusion of two persons who died within one year of the baseline study and 22 with inadequate polysomnography data, the sample comprised 1522 persons.

It is important to clarify that the Wisconsin Sleep Cohort is an observational study of a random sample of community adults.27 Thus, cohort participants are not patients referred for a clinical sleep diagnostic evaluation. Participants are not given diagnoses and are not treated or referred to a specific clinic for treatment. A passive method of informing participants of their polysomnography findings is used. Participants are given a summary report of their sleep study, with the number of apneas and hypopneas detected during their study and other details about their sleep duration and sleep architecture. The report is also sent to the participant’s health care provider. The report stresses that this is a research study with the aim of determining how SDB is related to adverse health outcomes and thus test results cannot be considered a diagnosis, and participants should contact their doctor if they have unsatisfactory sleep regardless of their study report. However, participants with an AHI of 15 or greater are advised that frequent breathing pauses are linked to health problems and they are advised to talk to their health care provider about their sleep report.

Data Collection

Baseline Assessment

The overnight protocol, described previously,27 was conducted in home-like bedrooms at the University of Wisconsin General Clinical Research Center. Upon arrival participants were given an orientation and informed written consent was obtained. After completion of the evening protocol, participants were encouraged to follow their usual sleep and wake times. Data for this investigation included responses to queries on life style, sleep habits, medical history, measures of weight (kg), height (cm), and girths of neck, waist, and hips (cm),29 multiple measures of blood pressure while seated, and polysomnographic assessment of SDB.

Eighteen-channel polysomnography (Grass model 78; Quincy, MA) recorded sleep state, using electroencephalography, electro-oculography, and electromyography; breathing, using respiratory inductance plethysmography (Respitrace; Ambulatory Monitoring, Ardsley, NY), nasal and oral airflow (ProTec thermocouples; Hendersonville, TN and Validyne Engineering Corp pressure transducer, Northridge, CA) and oxyhemoglobin saturation, using pulse oximetry (Ohmeda Biox 3740; Englewood, CO). Each 30-second epoch of the polysomnographic recordings was scored for sleep stage and apnea and hypopnea events by trained technicians and reviewed using standard criteria.30,31 Apnea was defined as cessation of airflow for ≥ 10 seconds and hypopnea was defined as a discernible reduction in breathing (sum of chest and abdominal excursions) with a reduction in oxyhemoglobin saturation of ≥ 4%. The summary parameter for SDB was mean number of apnea and hypopnea events/hour of sleep (apnea-hypopnea index, AHI).

Mortality Follow-up

Deaths in the cohort occurring up to March 1, 2008 were identified by matching social security numbers with 2 death record sources: the US Social Security Death Index (SSDI) and the Wisconsin State Bureau of Health Information and Policy, Vital Records Section. Matches on social security number were verified with participants’ age and sex. All deaths in Wisconsin (WI) were identified in the SSDI; in addition, 4 deaths occurring outside of WI were identified by the SSDI. Date of death was available on all decedents, and underlying and contributory causes of deaths were available from WI Vital Statistics. WI Vital statistics supplied a file with data on each individual death, including the ICD-9 codes and corresponding description as abstracted from individual death certificates. A sample of 30 death certificates was compared with abstracted records for accuracy, with 100% agreement. Cause of death was lacking for 3 of the 4 out of state deaths and 2 of the WI deaths.

Data Analysis

Variables

Sleep Disordered Breathing Status

Widely-used cutpoints, chosen a priori, were used to create the following SDB severity categories: No SDB (AHI < 5); Mild (AHI ≥ 5 < 15); Moderate (AHI ≥ 15 < 30); and Severe (AHI ≥ 30).

Mortality Status

Based on deaths recorded to March 2008, vital status was coded as alive or dead. Underlying and contributing causes cat-
gested with ICD-9 coding, were used to create the following cause-specific death categories:

1) Cardiovascular and stroke, including acute myocardial infarction, acute ischemic heart disease, heart failure with underlying chronic ischemic heart disease, stroke, atrial fibrillation and flutter, sudden cardiac arrest, cardiac dysrhythmias with underlying chronic ischemic heart disease, cardiomyopathy, and pulmonary hypertension;

2) Fatal events, including motor vehicle and motorcycle accidents, falls, injuries, and suicide;

3) Cancer, including cancer of the lung, bladder, breast, brain, and leukemia;

4) Other.

Covariables

Variables were created for: alcohol use (number of drinks/week), cigarette smoking (current or not), educational level (6 categories of school attainment), cardiovascular disease, stroke, diabetes (based on self-report of physician-diagnosis), hypertension (based on average of 3 measures of BP: systolic BP ≥ 140 mm Hg or diastolic ≥ 90 mm Hg or use of antihypertensive medication), self- rated general health (excellent, very good, good, fair, poor), and CPAP use for SDB (based on “usual use” at least 4 nights/week, reported at baseline or any follow-up visit). Variables for excessive daytime sleepiness included having excessive daytime sleepiness that interferes with daily living (yes, no), usual frequency (5 semi-quantitative categories) of excessive daytime sleepiness, and of feeling unrested, regardless of sleep duration. BMI (weight in kilograms divided by height in meters squared), neck girth, waist-hip ratio, total cholesterol, sleep duration (min/night), and age (y) at baseline were continuous variables.

Statistical Analysis

SAS software (SAS Institute, Version 9.1.3) and S plus (version 8) were used. Person-years were accumulated from baseline study to date of death or March 1, 2008. We computed all-cause and cardiovascular mortality rates (deaths/1000 person-years) and 95% confidence intervals (CI) by SDB categories at baseline. Kaplan-Meier techniques were used to compare survival by SDB categories, with log-rank test to assess differences. Cox proportional hazards regression was used to estimate adjusted hazard ratios and 95% CIs using SAS PHREG software. Trends were examined by testing the significance of SDB categories as a linear term. With multiple variable models, we examined sex, linear and quadratic terms for age and BMI, waist-hip ratio, neck girth, smoking, alcohol use, educational status, general health status, total cholesterol, and sleep duration as potential confounding factors. Diagnosed disorders were explored as possible mediating factors. Interactions of SDB with age, sex, and excessive daytime sleepiness in predicting mortality were examined. Analyses were repeated after excluding participants who reported use of CPAP. Diagnostic and residual plots were examined to test the proportional hazards assumptions.

Table 1—Description of Sample (n = 1522) by Sleep-Disordered Breathing Category

<table>
<thead>
<tr>
<th>Apnea Hypopnea Index Category</th>
<th>Total</th>
<th>None</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 1522</td>
<td>n = 1157</td>
<td>n = 220</td>
<td>n = 82</td>
<td>n = 63</td>
</tr>
<tr>
<td>Baseline characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuous variables, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>48 (8)</td>
<td>47 (8)</td>
<td>50 (8)</td>
<td>50 (8)</td>
<td>50 (9)</td>
</tr>
<tr>
<td>Body mass index, median kg/m²</td>
<td>28.6</td>
<td>27.6</td>
<td>31.5</td>
<td>33.3</td>
<td>37.2</td>
</tr>
<tr>
<td>Alcoholic drinks/week</td>
<td>2 (6)</td>
<td>2 (6)</td>
<td>2 (6)</td>
<td>2 (4)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Binary variables, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>274 (18)</td>
<td>214 (19)</td>
<td>36 (16)</td>
<td>12 (15)</td>
<td>12 (19)</td>
</tr>
<tr>
<td>Sex, male</td>
<td>839 (55)</td>
<td>589 (51)</td>
<td>142 (65)</td>
<td>59 (72)</td>
<td>49 (78)</td>
</tr>
<tr>
<td>Cardiovascular disease*</td>
<td>54 (4)</td>
<td>30 (3)</td>
<td>11 (5)</td>
<td>8 (10)</td>
<td>5 (8)</td>
</tr>
<tr>
<td>Hypertension*</td>
<td>495 (33)</td>
<td>312 (27)</td>
<td>95 (43)</td>
<td>46 (56)</td>
<td>42 (69)</td>
</tr>
<tr>
<td>Diabetes*</td>
<td>50 (3)</td>
<td>27 (2)</td>
<td>11 (5)</td>
<td>5 (6)</td>
<td>7 (11)</td>
</tr>
<tr>
<td>Stroke*</td>
<td>8 (0.5)</td>
<td>4 (0.4)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>4 (6)</td>
</tr>
<tr>
<td>Excessive daytime sleepiness</td>
<td>371 (25)</td>
<td>266 (23)</td>
<td>54 (25)</td>
<td>81 (35)</td>
<td>23 (37)</td>
</tr>
<tr>
<td>Education beyond high school</td>
<td>1124 (74)</td>
<td>876 (76)</td>
<td>149 (69)</td>
<td>57 (70)</td>
<td>42 (68)</td>
</tr>
<tr>
<td>Very good or excellent health**</td>
<td>1001 (69)</td>
<td>808 (74)</td>
<td>130 (61)</td>
<td>37 (48)</td>
<td>26 (43)</td>
</tr>
</tbody>
</table>

Deaths

Cause-specific, n (% of total deaths in AHI category)

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>None</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease and Stroke</td>
<td>25 (31)</td>
<td>12 (26)</td>
<td>6 (38)</td>
<td>2 (33)</td>
<td>5 (42)</td>
</tr>
<tr>
<td>Cancer</td>
<td>37 (46)</td>
<td>22 (48)</td>
<td>6 (38)</td>
<td>4 (67)</td>
<td>5 (42)</td>
</tr>
<tr>
<td>Injury, suicide</td>
<td>7 (9)</td>
<td>4 (9)</td>
<td>2 (12.5)</td>
<td>0 (0)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Other</td>
<td>6 (8)</td>
<td>4 (9)</td>
<td>2 (12.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Unknown</td>
<td>5 (6)</td>
<td>4 (9)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Total deaths, n (%)</td>
<td>80 (100)</td>
<td>46 (100)</td>
<td>16 (100)</td>
<td>6 (100)</td>
<td>12 (100)</td>
</tr>
</tbody>
</table>

*physician-diagnosed condition, self reported at baseline protocol

**Self-rated health evaluation

SLEEP, Vol. 31, No. 8, 2008
addition, mortality rates and hazard ratios were also estimated after accounting for the sample weighting. The estimates from the weighted and unweighted analyses did not differ.

RESULTS

Baseline characteristics of the sample and causes of death are shown in Table 1. The mean observation period of the cohort of 1522 men and women was 13.8 years (range, 1.5-18.7), for a total of 20,963 person-years. The average age at death was 61.1 years (range, 34-75). Cardiovascular mortality accounted for 26% of all deaths among persons without SDB at baseline and 42% of all deaths in persons with severe SDB at baseline.

Kaplan-Meier survival curves (Figure 1) illustrate the decrease in survival with increasing SDB category in the total sample of 1522 participants (Panel A) and in the sample after excluding participants (n = 126) who had reported CPAP use (Panel B). Survival was significantly lower with increasing SDB severity (P < 0.0001). The decrease in survival with SDB not treated with CPAP was markedly greater.

The all-cause mortality rate /1000 person-years (Table 2) for those with either mild or moderate SDB (AHI 5-15 and 15-30) at baseline were nearly double the rate among those without SDB (AHI < 5). The all-cause death rate was highest for severe SDB, at 14.6/1000 person-years. There was a clear trend of increased cardiovascular mortality with increasing severity of baseline SDB.

Hazard ratios for all-cause mortality, adjusted for sex, and linear and quadratic terms for age and BMI, were significantly increased with SBD severity (P-trend = 0.008) (Table 3). The adjusted hazard ratio (95% CI) for all-cause mortality for severe versus no SDB at baseline was 3.0 (1.4, 6.3). These hazard ratios were not decreased after further adjustment for smoking, alcohol use, general health status, educational status, neck girth, waist-hip ratio, sleep duration, and total cholesterol; the fully adjusted hazard ratio (95% CI) for mortality with severe vs no SDB was 5.9 (2.6, 13.3). We did not consider this model robust, for several reasons, including multicollinearity and potential model instability due to outliers and influential points (of great concern with a small number of outcomes). With 80 deaths as the outcome, we chose the parsimonious model with adjustment for BMI, BMI-squared (BMF^2), age, age-squared (age^2), and sex as the basic model for other analyses. However, we describe the above expanded model to show that the hazard ratio for mortality with SDB in the basic model is not overestimated by failure to include common risk factors for mortality.

In addition, mortality risk in our data was increased by the hallmark risk factors for mortality, including age, smoking, CVD risk factors, and general health status, increasing confidence in generalizability.

We explored the potential intermediary effects of chronic disorders as pathways from SDB to death, by examining the effect on the hazard ratio for all-cause mortality with SDB by adding variables for hypertension and physician-diagnosed CVD, stroke, and diabetes to the regression model simultaneously and singly. As seen in Table 4, the all-cause mortality hazard ratio with severe SDB changed from 3.0 to 2.7, (P = 0.01), indicating the net mortality risk with severe SDB explained by chronic disorders was less than might be expected. Adjusted hazard ratios for mortality associated with mild or moderate SDB were negligible. After single addition of the intermediary variables to examine the effect of each comorbid condition, adjusted hazard ratios for mortality with severe versus no SDB at baseline were: 3.1 (P = 0.003) after adding cardiovascular disease; 2.9 (P < 0.001) after adding stroke; 2.7 (P = 0.01) after adding hypertension; and 2.4 (P = 0.03) after adding diabetes. In addition to interest in how the SDB-mortality risk is explained by overt, diagnosed disorders, it is possible that the comorbidity is a marker for unmeasured confounding factors, or that stroke or CVD cause SDB. To address these potentially ambiguous cause-effect relationships, 8 participants reporting a stroke prior to baseline evaluation and 43 reporting CVD were excluded from the regression analyses (Table 5). Hazard ratios for mortality according to SDB status were not affected by this exclusion.

We found no statistically significant interactions between SDB and age, sex, or excessive daytime sleepiness with regard to mortality risk (all P > 0.1). Because the lack of interaction of SDB and sleepiness with regard to mortality risk has im-

### Table 2—All-Cause and Cause-Specific Mortality Rates Per 1000 Person-Years

<table>
<thead>
<tr>
<th>Baseline AHI category</th>
<th>n</th>
<th>All-cause mortality</th>
<th>Cardiovascular mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Deaths</td>
<td>Rate per 1000 person-years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(n (%))</td>
<td>(95% CI)</td>
</tr>
<tr>
<td>None: 0 - &lt; 5</td>
<td>1157</td>
<td>46 (4.0)</td>
<td>2.85 (2.09, 3.80)</td>
</tr>
<tr>
<td>Mild: 5 - &lt; 15</td>
<td>220</td>
<td>16 (7.3)</td>
<td>5.54 (3.16, 8.99)</td>
</tr>
<tr>
<td>Moderate: 15 - &lt; 30</td>
<td>82</td>
<td>6 (7.3)</td>
<td>5.42 (1.99, 11.8)</td>
</tr>
<tr>
<td>Severe: ≥ 30</td>
<td>63</td>
<td>12 (19.1)</td>
<td>14.6 (7.52, 25.4)</td>
</tr>
</tbody>
</table>

### Table 3—Mortality Risk with Sleep-Disordered Breathing (n = 1522): Adjusted Hazard Ratios*

<table>
<thead>
<tr>
<th>Baseline AHI category</th>
<th>All-cause mortality Hazard Ratio (95% CI)</th>
<th>Cardiovascular mortality Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None: 0 - &lt; 5</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Mild: 5 - &lt; 15</td>
<td>1.6 (0.9, 2.8)</td>
<td>1.8 (0.7, 4.9)</td>
</tr>
<tr>
<td>Moderate: 15 - &lt; 30</td>
<td>1.4 (0.6, 3.3)</td>
<td>1.2 (0.3, 5.8)</td>
</tr>
<tr>
<td>Severe: ≥ 30</td>
<td>3.0 (1.4, 6.3)</td>
<td><em>adjusted for age, age^2, sex, body mass index, and body mass index^2</em></td>
</tr>
<tr>
<td></td>
<td>P trend = 0.008</td>
<td>P trend = 0.12</td>
</tr>
</tbody>
</table>

*adjusted for age, age^2, sex, body mass index, and body mass index^2*.

AHI denotes number of apnea and hypopnea events per hour of sleep, CI denotes confidence interval.
applications regarding treatment of SDB patients who are not sleepy, we compared the adjusted hazard ratios for morbidity with SDB after stratification on several sleepiness variables defined by frequency of “feeling excessive daytime sleepiness,” frequency of “not feeling rested regardless of hours of sleep duration,” and experiencing “extreme sleepiness, beyond fatigue, that interferes with daily life.” Regression performed on each strata showed severe SDB either with or without sleepiness was associated with increased mortality: adjusted hazard ratios for mortality with severe SDB ranged from 2.0-3.9 for the “sleepy” strata, and from 2.8-3.8 for the “not sleepy” strata.

Although cardiovascular death rates were elevated for those with SDB at baseline, the adjusted hazard ratios for cardiovascular mortality with SDB were not statistically significant (Table 3). All associations between SDB and mortality were markedly stronger after excluding 126 participants who had reported regular CPAP use (Table 6). Compared to individuals without SDB, the adjusted mortality risks were highest for those with severe SDB who had not used CPAP: the hazard ratio for all-cause mortality was 3.8 (95% CI, [1.6, 9.0]) and the hazard ratio (95% CI) for cardiovascular mortality was 5.2 (1.4, 19.2).

**DISCUSSION**

Mortality follow-up of the Wisconsin Sleep Cohort, comprising 20,963 person-years, indicates that severe SDB is significantly associated with a 3-fold increased all-cause mortality risk (P < 0.0008), independently of age, sex, BMI, and other potential confounders. After excluding persons who had reported using CPAP, the associations were even more striking: adjusted hazard ratios (95% CI) for all-cause mortality comparing participants with severe SDB to those without SDB were 3.8 (95% CI, [1.6, 9.0]) Similarly, after excluding persons who had used CPAP from the sample, the hazard ratio for cardiovascular mortality increased in magnitude and statistical significance, to 5.2 (1.4, 19.2). Although mortality risk was 50% greater for those with mild and moderate SDB compared to those without SDB, the estimates were not statistically significant.

Table 4—Mortality Risk with Sleep-Disordered Breathing (n = 1522): Influence of Comorbidity

<table>
<thead>
<tr>
<th>Baseline AHI category</th>
<th>Hazard ratio* for all-cause mortality, accounting for comorbidity</th>
<th>Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None: 0 - &lt; 5</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Mild: 5 - &lt; 15</td>
<td>1.5 (0.8, 2.8)</td>
<td></td>
</tr>
<tr>
<td>Moderate: 15 - &lt; 30</td>
<td>1.3 (0.5, 3.2)</td>
<td></td>
</tr>
<tr>
<td>Severe: ≥ 30</td>
<td>2.7 (1.3, 5.7)</td>
<td></td>
</tr>
</tbody>
</table>

*model includes variables for age, age², sex, body mass index, body mass index², hypertension (BP ≥ 140 systolic or ≥ 90 diastolic or use of antihypertensive medication), self-reported diagnosis of diabetes, coronary artery disease, cardiovascular disease, heart failure, myocardial infarction, cardiac surgery, and stroke. AHI denotes number of apnea and hypopnea events per hour of sleep, CI denotes confidence interval.

**Figure 1**—Kaplan-Meier estimates of survival probability according to sleep-disordered breathing severity for A) Total sample and B) Sample excluding 126 CPAP treated participants.

A. Kaplan-Meier estimates of the probability of survival (shown with y-axis truncated at 50% survival) according to sleep-disordered breathing severity: none (AHI < 5), mild (AHI > 5, < 15), moderate (AHI > 15, < 30) and severe (AHI > 30), total sample (n = 1522); long-rank test for differences in survival by SDB category: P < 0.00001; AHI is mean number of apnea and hypopnea episodes/hr of sleep.

B. Kaplan-Meier estimates of the probability of survival (shown with y-axis truncated at 50% survival) according to untreated* sleep-disordered breathing category (none (AHI < 5), mild (AHI > 5, < 15), moderate (AHI > 15, < 30) and severe (AHI > 30), *participants who had used CPAP were excluded (n = 1396); long-rank test for differences in survival by SDB category: P < 0.00001; AHI is mean number of apnea and hypopnea episodes/hr of sleep.
Although most previous reports support a role of SDB in mortality, interpretation has been limited by concern with clinic referral biases. Our findings, based on mortality follow-up of a general population cohort with polysomnographically determined SDB at baseline, affirm mortality as a significant part of the public health burden of SDB.

In the first follow-up study of sleep apnea patients, He et al. reported that premature death was associated with severe sleep apnea (> 20 vs < 20 apnea/hour), but survival was not decreased for patients treated with CPAP. Although limited by small sample size, clinical referral biases, and incomplete follow-up, the alarming findings of this study made further investigation of a sleep apnea–mortality link imperative. Since then, clinical studies with larger sample sizes, adjustment for confounding factors, and more complete follow-up continue to find an increased mortality risk with SDB. In the largest clinic sample conducted on men, the mortality risk differed by comparison group: mortality rates of clinic patients compared with population statistics were higher only for men less than 50 years of age, but the all-cause mortality hazard ratio was significantly greater for patients with > 30 vs < 10 respiratory disturbances/hour. Thus, concerns with referral biases and lack of optimal comparison groups remain, limiting interpretation of findings from patient samples. Although a bias favoring evaluation of patients with both SDB and significant comorbidity is of most concern, potentially causing overestimation of risk, other biases associated with time period, referral patterns, and SDB awareness may lead to underestimation of risk.

The consistency of our population-based findings of elevated mortality risk for severe SDB with the results of clinic-based studies over the past 20 years increases confidence in the validity of a significant role of SDB in mortality. In addition to supporting the findings of He et al., our findings are similar to those from 2 recent sleep clinic-based studies using the same polysomnographic methods and apnea and hypopnea definitions as used in our study. Yaggi et al. in a 3.5-year follow-up of a large sample of patients evaluated for sleep apnea, found a 2-fold increased adjusted risk for either incident stroke or death for patients diagnosed with sleep apnea (mean AHI = 35) versus not diagnosed (mean AHI = 2). Marin et al. reported 3-fold greater odds of cardiovascular mortality in patients with severe sleep apnea, compared with community controls and patients without SDB.

We found a significant, strong increase in cardiovascular mortality (adjusted hazard ratio (95% CI) = 5.2 [1.4, 19.2]) with severe SDB only after CPAP users were excluded, suggesting that CPAP was protective particularly against cardiovascular death. This finding is consistent with results of several clinic studies reporting greater mortality risk with untreated SDB among cardiovascular and stroke patients. Similarly, recent clinical studies of patients with both SDB and cardiovascular or stroke morbidity suggest CPAP decreases heart failure and stroke hospitalization time, and improves survival. In addition, there is evidence that CPAP use may reduce hypertension risk.

Although our findings are consistent with a protective effect of CPAP against mortality, it is important to note limitations in our data on CPAP use, including lack of information on consistent use over time or effectiveness of air pressure level to prevent airway closure. Participants with SDB detected in our study are not diagnosed or randomized to treatment. Participants who independently choose to seek care and treatment may have health characteristics that differ from those who do not seek care. Thus, CPAP use may be a marker of increased healthy behaviors that protect against death. Consequently, our data cannot establish how CPAP contributes to lower death rates.

We explored baseline medical disorders as possible pathways through which SDB may contribute to mortality. The association between SDB and mortality was only partly explained by hypertension and clinically diagnosed cardiovascular disease, diabetes, or stroke. However, without knowledge of appropriate latent or induction periods over which SDB may affect new or underlying morbidity, it is difficult to speculate on mechanisms through which SDB contributed to mortality in our data. The average time to death for participants with SDB was 11.8 years, indicating that SDB is not an acutely fatal disorder. Furthermore, we do not know how long participants had SDB prior to their baseline study, so we cannot validly estimate the time course from baseline to death with these data.

Our findings are based on a cohort with little ethnic diversity (95% white) and persons who were employed at recruitment.
While validity in our findings with respect to white adults with adequate income and access to medical care is increased by the homogeneity of the sample, it is likely that our findings may underestimate the mortality risk of SDB in other ethnic groups or the lowest socioeconomic strata where there is poor awareness and access to health care.

The benefit of treating SDB patients who are not sleepy is controversial. Furthermore, studies have indicated that sleepiness is not a common SDB symptom in patients with both cardiovascular disease and SDB. Our analyses indicated that SDB, irrespective of excessive sleepiness symptoms, was associated with increased mortality. This finding, and the striking high cardiovascular mortality risk in untreated severe SDB, suggests that SDB treatment should not be contingent on daytime sleepiness symptoms.

CONCLUSIONS

Eighteen-year follow-up of the Wisconsin Sleep Cohort provides new insights on mortality as part of the public health burden of SDB. Participants with severe SDB at baseline had a statistically significant (P < 0.01) 3-fold greater risk (with 95% confidence interval ranging from 1.4-6.3) of all-cause mortality compared to those without SDB, independent of sex, BMI, age, and other potential confounders. However, it is possible that residual confounding due to unmeasured or inadequately measured factors contributes to bias in the estimate. Given the inevitable increase in SDB prevalence with the contemporary epidemic of obesity, the 4- to 5-fold increase in all-cause and cardiovascular mortality associated with untreated, severe SDB is of high concern. Although further studies are needed to quantify the proportion of mortality that could be lowered by prevention or treatment of SDB, the results of our study can be applied directly to current health care practice. Our findings of significant mortality risk with untreated SDB, in conjunction with prior evidence that CPAP can effectively treat severe SDB, underscore the immediate need for heightened clinical recognition and treatment of SDB, indicated by frequent episodes of apnea and hypopnea, irrespective of symptoms of sleepiness.

ACKNOWLEDGMENTS

We thank Kathryn Pluff, Linda Evans, Amanda Rasmuson, and Katherine Kenison for their technical expertise and Joyce Knapton for assistance with Wisconsin vital records.

Study performed at the University of Wisconsin-Madison, School of Medicine and Public Health, Madison WI. Financial Support: NIH grants R01:HL62252, R01:AG14124, and RR:03186.

REFERENCES


SLEEP, Vol. 31, No. 8, 2008


